Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3-day IV vs 3-day IV + 7-day oral antibiotics for acute pyelonephritis in young children
2021-005627-21Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amikacin, ceftriaxone, cefixime, sulfamethoxazole and trimethoprim in acute pyelonephritis (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: renal scarring. Started Jun 2022; status: active.
02
Drugs
amikacinceftriaxonecefiximesulfamethoxazoletrimethoprim
03
Conditions
acute pyelonephritis
Beyond the preview
Go deeper on 2021-005627-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005627-21.